

Research

IMCB NCC MPI Singapore Oncogenome Program is a collaborative unit funded by Max Planck - Department of Biochemistry, National Cancer Centre Singapore and Institute of Molecular and Cell Biology. The unit houses both basic and clinical research, providing a synergistic research environment for translational work in the field of oncology. The unit serves to link both clinicians and basic scientists with common research interests to explore, discuss, and develop ideas.

As a start, 3 clinicians from the National Cancer Center Singapore will function as adjunct investigators in the laboratory.



Darren Wan-Teck Lim

Dr Darren Wan-Teck Lim is a medical oncologist. He graduated with MBBS from the National University of Singapore in 1993. He is Director of the SingHealth Investigational Medicine Unit. He was a visiting research fellow in pharmacogenomics and thoracic oncology at the Washington University School of Medicine, St Louis. His research interests are in early phase clinical trials with biomarker correlates, with areas of specific interest in circulating tumor cells. He is also Co-Group Leader for the laboratory.



Gopal Iyer

Dr Gopal Iyer is head and neck cancer surgeon. He graduated with MBBS from the National University of Singapore in 1998 with the Lee Kuan Yew Gold Medal and the Gibbs Gold Medal. He also holds a PhD in Cancer Genomics from Cambridge University. He completed his postdoctoral fellowships with the Cancer Genomics Program, Cambridge University and at the Genome Institute of Singapore. His research interests are in squamous cell carcinoma of the head and neck focusing on the biology of head and neck cancer stem cells and

investigating novel drug targets and pathways in head and neck cancer. He is also the recipient of the NMRC Clinician Scientist Award for his research in 2012.



Daniel Shao-Weng Tan

Dr Daniel Shao-Weng Tan is a medical oncologist. He graduated from University College London, with an Intercalated Bachelor of Science degree in Tumour Biology, 1st Class (Honours), and MBBS from St. Bartholomew's and Royal London Hospital School of Medicine and Dentistry. He has received the ASCO Cancer Foundation Young Investigator Award and ASCO Cancer Foundation Merit Award. His research interests are in drug development in phase I trials. He is directly involved in developing protocols testing new drug targets and combinations in various cancers. His areas of specific interest are in drug resistance, with particular emphasis on lung cancer and the PI3K pathway.

Capabilities

- Molecular profiling of cancer to identify novel targets
- Functional characterization of oncogenes
- Primary cancer cell lines and xenograft model for disease characterization and drug testing
- Small molecule inhibitor development under the SOG program
- Investigate and repurpose established drugs